ALEXION PHARMACEUTICALS, INC.

ALEXION PHARMACEUTICALS, INC. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
1992-01-01
Employees
3.8K
Market Cap
-
Website
http://www.alexion.com

Study of Danicopan in Participants With Hepatic Impairment

Phase 1
Completed
Conditions
Interventions
First Posted Date
2018-06-13
Last Posted Date
2021-08-20
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
16
Registration Number
NCT03555539
Locations
🇺🇸

Clinical Trial Site, Orlando, Florida, United States

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab

First Posted Date
2018-03-21
Last Posted Date
2023-12-12
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
12
Registration Number
NCT03472885
Locations
🇬🇧

Clinical Study Site, London, United Kingdom

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

First Posted Date
2018-03-09
Last Posted Date
2023-08-21
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
22
Registration Number
NCT03459443
Locations
🇳🇱

Clinical Study Site, Nijmegen, Netherlands

A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria

Phase 3
Completed
Conditions
Interventions
First Posted Date
2018-01-23
Last Posted Date
2023-03-27
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
13
Registration Number
NCT03406507
Locations
🇬🇧

Clinical Trial Site, London, United Kingdom

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2018-01-18
Last Posted Date
2024-06-17
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
214
Registration Number
NCT03403205
Locations
🇬🇧

Research Site, London, United Kingdom

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

First Posted Date
2017-12-27
Last Posted Date
2021-08-20
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
14
Registration Number
NCT03384186
Locations
🇬🇧

Clinical Trial Site, Ruddington, Nottingham, United Kingdom

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

First Posted Date
2017-12-11
Last Posted Date
2022-10-14
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
13
Registration Number
NCT03369236
Locations
🇬🇧

Clinical Study Site, London, United Kingdom

Study Evaluating Betrixaban in Pediatric Participants

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2017-11-17
Last Posted Date
2024-01-12
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
21
Registration Number
NCT03346083
Locations
🇺🇸

Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States

🇷🇺

Children's City Clinical Hospital, Moscow, Russian Federation

🇷🇺

Pirogov Russian National Research Medical University, Moscow, Russian Federation

and more 17 locations

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2017-06-09
Last Posted Date
2023-03-14
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
8
Registration Number
NCT03181633
Locations
🇳🇿

Clinical Trial Site, Auckland, New Zealand

Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)

First Posted Date
2017-04-27
Last Posted Date
2024-03-15
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
34
Registration Number
NCT03131219
Locations
🇬🇧

Research Site, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath